National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Finerenone (Kerendia®). HTA ID: 22012

Finerenone (Kerendia®) is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.

 

NCPE Assessment Process Ongoing
Rapid review commissioned 21/02/2022
Rapid review completed 15/03/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of finerenone compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 01/04/2022
Pre-submission consultation with Applicant 24/05/2022
Full HTA submission received from Applicant 10/11/2022
Current Status Full HTA submission received from Applicant